[1]高敏婵,王鹏,胡泽瑞,等.卡帕塞替尼对类风湿关节炎成纤维样滑膜细胞MH7A增殖、迁移、侵袭、凋亡及自噬的影响实验研究[J].陕西医学杂志,2025,54(6):742-747.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.004]
　GAO Minchan,WANG Peng,HU Zerui,et al.An experimental study of the effect of capasertinib on the proliferation,migration,invasion,apoptosis and autophagy of fibroblast-like synoviocytes MH7A in rheumatoid arthritis[J].,2025,54(6):742-747.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.004]
点击复制

卡帕塞替尼对类风湿关节炎成纤维样滑膜细胞MH7A增殖、迁移、侵袭、凋亡及自噬的影响实验研究

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年6期
页码:
742-747
栏目:
基础研究
出版日期:
2025-06-05

文章信息/Info

Title:
An experimental study of the effect of capasertinib on the proliferation,migration,invasion,apoptosis and autophagy of fibroblast-like synoviocytes MH7A in rheumatoid arthritis
作者:
高敏婵; 王鹏; 胡泽瑞; 葛王舒琦; 江澳; 张鑫; 赵存喜
（安徽医科大学公共卫生学院，安徽 合肥 230032）
Author(s):
GAO Minchan; WANG Peng; HU Zerui; GEWANG Shuqi; JIANG Ao; ZHANG Xin; ZHAO Cunxi
(School of Public Health,Anhui Medical University,Hefei 230032,China)
关键词:
类风湿关节炎; 卡帕塞替尼; MH7A细胞; 增殖; 迁移; 侵袭; 凋亡; 自噬
Keywords:
Rheumatoid arthritis; AZD5363; MH7A cells; Proliferation; Migration; Invasion; Apoptosis; Autophagy
分类号:
R -33
DOI:
DOI:10.3969/j.issn.1000-7377.2025.06.004
文献标志码:
A
摘要:
目的：探讨蛋白激酶B（AKT）抑制剂卡帕塞替尼（AZD5363）对类风湿关节炎（RA）成纤维样滑膜细胞MH7A增殖、迁移和侵袭、凋亡以及自噬的影响。方法：将MH7A细胞随机分为对照组（无药物干预）、低浓度组(含3 μmol/L AZD5363高糖培养基培养)、中浓度组(含6 μmol/L AZD5363高糖培养基培养)和高浓度组(含9 μmol/L AZD5363高糖培养基培养)。采用CCK-8法检测细胞增殖情况；采用流式细胞术和Transwell实验检测细胞凋亡、迁移和侵袭情况；采用Western blot检测细胞凋亡相关蛋白[B淋巴细胞瘤2（Bcl2）和Bcl2相关X蛋白（Bax）]、细胞迁移与侵袭相关蛋白[基质金属蛋白酶-1（MMP-1）和MMP-2]、自噬相关蛋白[自噬相关基因5（ATG5）、自噬相关蛋白7（ATG7）、微管相关蛋白1A/1B-轻链3（LC3Ⅱ/Ⅰ）、螯合体1（p62）]以及AKT、磷酸化AKT（p-AKT）蛋白表达。结果：MH7A细胞经过不同浓度AZD5363处理后，与对照组比较，随着药物浓度增加，细胞活力降低，细胞凋亡率增加，细胞迁移和侵袭率降低，Bcl2、MMP-1、MMP-2、ATG5、ATG7及LC3Ⅱ/Ⅰ蛋白表达降低，Bax、p62蛋白表达升高（均P<0.05）。结论：AZD5363可以明显抑制MH7A细胞增殖、迁移、侵袭及自噬，同时显著促进其凋亡。
Abstract:
Objective:To investigate the effects of the protein kinase B (AKT) inhibitor capivasertib (AZD5363) on the proliferation,migration and invasion,apoptosis and autophagy in rheumatoid arthritis (RA) fibroblast-like synoviocyte MH7A.Methods：MH7A cells were randomly divided into control group (no drug intervention),low concentration group (cultured with 3 μmol/L AZD5363 in high glucose medium),medium concentration group (cultured with 6 μmol/L AZD5363 in high glucose medium) and high concentration group (cultured with 9 μmol/L AZD5363 in high glucose medium).Cell proliferation was detected by cell counting kit-8 assay.Apoptosis was detected using flow cytometry.Transwell assay was used to detect cell migration and invasion.Western blot assay was used to detect apoptosis-associated proteins B-lymphoblastoma-2 gene (Bcl2),Bcl2-Associated X protein (Bax),and cell migration and invasion-associated protein matrix metalloproteinase-1 (MMP-1) and MMP-2,and autophagy-associated protein autophagy-associated gene 5 (ATG5),ATG7,microtubule-associated protein 1A/1B-light chain 3 (LC3Ⅱ/Ⅰ),chelator 1 (p62),and AKT,phosphorylated AKT (p-AKT).Results:After MH7A cells were treated with different concentrations of AZD5363,compared with the control group,with the increase of drug concentration,the cell viability was decreased,the apoptosis rate was significantly increased,and the cell migration and invasion rate was decreased,and the protein expressions of Bcl2,MMP-1,MMP-2,ATG5,ATG7 and LC3Ⅱ/Ⅰ were decreased,and the protein expressions of Bax and p62 were increased (all P<0.05).Conclusion:AZD5363 can significantly inhibit the proliferation,migration,invasion and autophagy of MH7A cells,and significantly promote their apoptosis.

参考文献/References:

[1]王一晨,谷慧敏,陈宇华,等.孟德尔随机化在类风湿关节炎相关研究中的应用[J].陕西医学杂志,2024,53(11)：1562-1566.
[2]SCHERER H U,HUPL T,BURMESTER G R.The etiology of rheumatoid arthritis[J].J Autoimmun,2020,110：102400.
[3]FINCKH A,GILBERT B,HODKINSON B,et al.Global epidemiology of rheumatoid arthritis[J].Nat Rev Rheumatol,2022,18(10)：591-602.
[4]令垚,张文滨,王仕鸿,等.1990—2021年中国类风湿性关节炎疾病负担变化趋势分析及预测研究[J/OL].中国全科医学,1-9[2024-12-27].http：//kns.cnki.net/kcms/detail/13.1222.R.20241026.0712.014.html.
[5]KUCUKDEVECI A A.Nonpharmacological treatment in established rheumatoid arthritis[J].Best Pract Res Cl Rh,2019,33(5)：101482.
[6]NYGAARD G,FIRESTEIN G S.Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes[J].Nat Rev Rheumatol,2020,16(6)：316-333.
[7]LIN L,LIN Y,HAN Z,et al.Understanding the molecular regulatory mechanisms of autophagy in lung disease pathogenesis[J].Front Immunol,2024,15：1460023.
[8]JIANG J,REN R,FANG W,et al.Lysosomal biogenesis and function in osteoclasts：A comprehensive review[J].Front Cell Dev Biol,2024,12：1431566.
[9]KARAMI J,MASOUMI M,KHORRAMDELAZAD H,et al.Role of autophagy in the pathogenesis of rheumatoid arthritis：Latest evidence and therapeutic approaches[J].Life Sci,2020,254：117734.
[10]许海艳,况南珍,张瑜娟,等.类风湿性关节炎治疗方法的研究进展[J].南昌大学学报（医学版）,2020,60(5)：97-102.
[11]CRAMP F.The role of non-pharmacological interventions in the management of rheumatoid-arthritis-related fatigue[J].Rheumatology,2019,58(Suppl 5)：v22-v28.
[12]周春瑜,陈艳林,付庭娜,等.中医辨治类风湿关节炎的研究进展[J].风湿病与关节炎,2020,9(10)：72-75.
[13]张丹,刘佳,何东仪,等.中医外治法在类风湿关节炎中的研究进展[J].陕西中医,2024,45(11)：1582-1585.
[14]SHIRLEY M.Capivasertib：First approval[J].Drugs,2024,84(3)：337-346.
[15]BANERJI U,DEAN E J,PREZ-FIDALGO J A,et al.A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers[J].Clin Cancer Res,2018,24(9)：2050-2059.
[16]ANDRIKOPOULOU A,CHATZINIKOLAOU S,PANOU-RGIAS E,et al.The emerging role of capivasertib in breast cancer[J].Breast,2022,63：157-167.
[17]TURNER N C,OLIVEIRA M,HOWELL S J,et al.Capivasertib in hormone receptor-positive advanced breast cancer[J].New Engl J Med,2023,388(22)：2058-2070.
[18]王小蕊,李文倩,解友邦,等.托法替尼联合传统DMARDs类药物治疗类风湿性关节炎临床效果观察[J].陕西医学杂志,2023,52(12)：1727-1730.
[19]FALCONER J,MURPHY A N,YOUNG S P,et al.Review：Synovial cell metabolism and chronic inflammation in rheumatoid arthritis[J].Arthritis Rheumatol,2018,70(7)：984-999.
[20]CORREIA C,LEE S H,MENG X W,et al.Emerging understanding of Bcl-2 biology：Implications for neoplastic progression and treatment[J].Biochim Biophys Acta,2015,1853(7)：1658-1671.
[21]赵帆,李佳钰,陆麒瑾,等.当归拈痛汤调控Fas/caspase-8通路促进类风湿关节炎滑膜成纤维细胞凋亡[J].南方医科大学学报,2020,40(8)：1119-1126.
[22]蒋晶,杨茜云,沈国强,等.基质金属蛋白酶3在类风湿关节炎患者中的临床意义[J].国际检验医学杂志,2022,43(1)：73-77.
[23]周亚婕,姚小强,郑先丽,等.经典针法治疗类风湿关节炎的实验研究进展[J].世界科学技术-中医药现代化,2021,23(11)：4359-4364.
[24]KORB-PAP A,BERTRAND J,SHERWOOD J,et al.Stable activation of fibroblasts in rheumatic arthritis-causes and consequences[J].Rheumatology (Oxford),2016,55(suppl 2)：ii64-ii67.
[25]CAO W,ZHANG J,WANG G,et al.Reducing-autophagy derived mitochondrial dysfunction during resveratrol promotes fibroblast-like synovial cell apoptosis[J].Anat Rec (Hoboken),2018,301(7)：1179-1188.
[26]UKO N E,GNER O F,MATESIC D F,et al.Akt pathway inhibitors[J].Curr Top Med Chem,2020,20(10)：883-900.
[27]XIE X,SHU R,YU C,et al.Mammalian AKT,the emerging roles on mitochondrial function in diseases[J].Aging Dis,2022,13(1)：157-174.

相似文献/References:

[1]卢北玲,史剑飞,彭 晶,等.CRP、RF及ASO检测在类风湿关节炎合并肺间质纤维化诊断中的价值[J].陕西医学杂志,2019,(6):803.
[2]孙芳芳,张 静△,范秀风.类风湿关节炎合并心血管损伤危险因素研究*[J].陕西医学杂志,2019,(10):1305.
[3]王 颖,白 琳,张 洁,等.抑制炎性细胞因子与类风湿关节炎合并急性心肌梗死患者颈动脉斑块相关性研究*[J].陕西医学杂志,2019,(12):1679.
[4]刘昌莲,贺冬冬,李晓明,等.艾拉莫德治疗类风湿关节炎疗效及对患者免疫炎症因子水平和骨代谢指标的影响*[J].陕西医学杂志,2020,49(5):603.
　LIU Changlian,HE Dongdong,LI Xiaoming,et al.Clinical efficacy of Iguratimod in the treatment of rheumatoid arthritis and its effect on the levels of immune inflammatory factors and the indexes of bone metabolism[J].,2020,49(6):603.
[5]刘兆宜,沈洲立,岳跃兵,等.类风湿关节炎并发动脉粥样硬化相关性研究进展*[J].陕西医学杂志,2020,49(11):1534.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.043]
　LIU Zhaoyi,SHEN Zhouli,YUE Yuebing,et al.Research progress on the correlation between rheumatoid arthritis and atherosclerosis[J].,2020,49(6):1534.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.043]
[6]李长超,柴艳梅,刘 丹,等.类风湿关节炎患者血清IL-13水平表达及对外周血单个核细胞中Th17细胞亚群分化的影响[J].陕西医学杂志,2021,50(2):197.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.018]
　LI Changchao,CHAI Yanmei,LIU Dan,et al.Expression of serum IL-13 in patients with rheumatoid arthritis and its effect on differentiation of Th17 cell subsets in PBMC[J].,2021,50(6):197.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.018]
[7]安 新,冯 超,高利常.类风湿关节炎患者血清白细胞介素-32、白细胞介素-17和白细胞介素-10表达水平及临床意义[J].陕西医学杂志,2021,50(12):1585.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.030]
　AN Xin,FENG Chao,GAO Lichang.Expression levels of serum interleukin-32,interleukin-17 and interleukin-10 in patients with rheumatoid arthritis and their clinical significance[J].,2021,50(6):1585.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.030]
[8]杨 婧,何家锐,孙红兵,等.沙利度胺对类风湿关节炎滑膜细胞及外周血单个核细胞分泌肿瘤坏死因子-α和血管内皮生长因子的影响及机制研究[J].陕西医学杂志,2022,51(12):1501.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.008]
　YANG Jing,HE Jiarui,SUN Hongbing,et al.Effects of thalidomide on secretion of TNF-α and VEGF in fibroblast-like synoviocytes and peripheral blood mononuclear cells in patients with rheumatoid arthritis and its mechanism[J].,2022,51(6):1501.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.008]
[9]王小蕊,李文倩,解友邦,等.托法替尼联合传统DMARDs类药物治疗类风湿性关节炎临床效果观察[J].陕西医学杂志,2023,52(12):1728.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.022]
　WANG Xiaorui,LI Wenqian,XIE Youbang,et al.Clinical effect of tofacitinib combined with traditional DMARDs in treatment of rheumatoid arthritis[J].,2023,52(6):1728.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.022]
[10]王一晨,谷慧敏,陈宇华,等.孟德尔随机化在类风湿关节炎相关研究中的应用[J].陕西医学杂志,2024,(11):1562.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.027]
　WANG Yichen,GU Huimin,CHEN Yuhua,et al.Application of Mendelian randomization in rheumatoid arthritis-related research[J].,2024,(6):1562.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.027]

备注/Memo

备注/Memo:
安徽省高等学校科研计划项目（2024AH040320，2022AH050653）
更新日期/Last Update: 2025-06-04